[Featured Stock] Medicox Signs Exclusive Sales Contract for Diagnostic Kit Products... Surges Over 13%
[Asia Economy Reporter Park Jihwan] Medicox is showing strong performance following the news that it has signed an exclusive distribution agreement to sell and distribute diagnostic kit products from Flexense, a company specializing in diagnostic kit research and development, throughout South Korea and all of Europe.
As of 9:58 AM on the 11th, Medicox is trading at 1,615 KRW, up 13.68% (195 KRW).
Hot Picks Today
"You Might Regret Not Buying Now"... Overseas Retail Investors Stirred by News of Record-Breaking Monster Stocks' IPOs
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Mistaken for the Flu, Left Untreated... Death Toll Surges as WHO Declares Emergency (Comprehensive)
- Jinwoo Sunim: "We Must Abandon the Extremes of Surviving by Defeating Others"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Flexense is a company that developed COVID-19 serological antibody diagnostic kits, saliva antigen diagnostic kits, and serological neutralizing antibody diagnostic kits by receiving technology transfers for COVID-19 antigen and neutralizing antibodies from the Korea Research Institute of Bioscience and Biotechnology and the Osong Advanced Medical Industry Promotion Foundation under the Ministry of Health and Welfare, respectively.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
